Premium
Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report
Author(s) -
Horai Yoshiro,
Ishikawa Hiroshi,
Iwanaga Nozomi,
Izumi Yasumori,
Matsuoka Yuki,
Miura Shiro,
Kawakami Atsushi
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13117
Subject(s) - certolizumab pegol , medicine , rheumatoid arthritis , vasculitis , prednisolone , dermatology , immunology , adalimumab , disease
What is known and objective Tumour necrosis factor‐α–blocking agents potentially cause vasculitis. However, no study has reported on the association between hypocomplementemic urticarial vasculitis (HUV) and certolizumab pegol (CZP) usage. Case description We present the first case of HUV development during CZP treatment for rheumatoid arthritis. Hypocomplementemic urticarial vasculitis improved after CZP was discontinued and the dose of oral prednisolone was increased. What is new and conclusion Clinicians should be aware about the potential development of HUV during CZP treatment, which is presumed to be safe considering its unique structural characteristics that differ from those of other tumour necrosis factor‐α–blocking agents.